STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients

Blood

Volumn 122, Issue 14, 2013, Pages 2453-2459

  Jerez, Andres ^a   Clemente, Michael J ^a   Makishima, Hideki ^a   Rajala, Hanna ^b   Goḿez Seguí, Ines ^a   Olson, Thomas ^c   McGraw, Kathy ^d   Przychodzen, Bartlomiej ^a   Kulasekararaj, Austin ^e   Afable, Manuel ^a   Husseinzadeh, Holleh D ^a   Hosono, Naoko ^a   LeBlanc, Francis ^c   Lagstrom̈, Sonja ^f   Zhang, Dan ^c   Ellonen, Pekka ^f   Tichelli, André ^g   Nissen, Catherine ^g   Lichtin, Alan E ^a   Wodnar Filipowicz, Aleksandra ^g   Mufti, Ghulam J ^e   List, Alan F ^d   Mustjoki, Satu ^b   Loughran Jr , Thomas P ^c   Maciejewski, Jaroslaw P ^a   more..

^a TAUSSIG CANCER INSTITUTE   (United States)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c PENN STATE CANCER INSTITUTE   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF HELSINKI   (Finland)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR15 ANTIGEN; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

ADULT; APLASTIC ANEMIA; ARTICLE; BONE MARROW DEPRESSION; CHROMOSOME 7; CLINICAL FEATURE; COHORT ANALYSIS; FEMALE; GENE MUTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LYMPHOCYTE CLONE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; CELL SEPARATION; FLOW CYTOMETRY; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUTATION; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ANEMIA, APLASTIC; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84887704112     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-494930     Document Type: Article

References (37)

1. Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood. 1993;82(1):1-14.
2. Gastl G, Niederwieser D, Marth C, et al. Human large granular lymphocytes and their relationship to natural killer cell activity in various disease states. Blood. 1984;64(1):288-295.
3. Saunthararajah Y, Molldrem JL, Rivera M, et al. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. Br J Haematol. 2001; 112(1):195-200.
4. Risitano AM, Maciejewski JP, Green S, Plasilova M, Zeng W, Young NS. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet. 2004;364(9431): 355-364.
5. Wlodarski MW, Gondek LP, Nearman ZP, Plasilova M, Kalaycio M, Hsi ED, Maciejewski JP. Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. Blood. 2006;108(8):2632-2641.
6. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al The German Aplastic Anemia Study Group. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med. 1991;324(19): 1297-1304.
7. Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008; 26(15):2505-2511.
8. Zeng W, Maciejewski JP, Chen G, Young NS. Limited heterogeneity of T cell receptor BV usage in aplastic anemia. J Clin Invest. 2001;108(5): 765-773.
9. Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 1995;85(11):3183-3190.
10. Koskela HL, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20): 1905-1913.
11. Jerez A, Clemente MJ, Makishima H, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120(15):3048-3057.
12. Swerdlow SH. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008.
13. Marsh JC, Ball SE, Cavenagh J, et al British Committee for Standards in Haematology. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1): 43-70.
14. Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17(7):2503-2516.
15. Dunbar AJ, Gondek LP, O'Keefe CL, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008;68(24):10349-10357.
16. Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood. 2009; 113(25):6403-6410.
17. Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117(21): e198-e206.
18. Gómez-Seguí I, Makishima H, Jerez A, et al. Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies [published online ahead of print June 14, 2013]. Leukemia.
19. Go RS, Tefferi A, Li CY, Lust JA, Phyliky RL. Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. Blood. 2000;96(10):3644-3646.
20. Evans HL, Burks E, Viswanatha D, Larson RS. Utility of immunohistochemistry in bone marrow evaluation of T-lineage large granular lymphocyte leukemia. Hum Pathol. 2000;31(10):1266-1273.
21. Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP Jr. The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood. 1997;89(1):256-260.
22. Bessler M, Mason PJ, Hillmen P, et al. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J. 1994;13(1):110-117.
23. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002;100(5): 1570-1574.
24. Shetty V, Mundle S, Alvi S, et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res. 1996;20(11-12):891-900.
25. Kitagawa M, Saito I, Kuwata T, et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia. 1997;11(12):2049-2054.
26. Kornblau SM, McCue D, Singh N, Chen W, Estrov Z, Coombes KR. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood. 2010; 116(20):4251-4261.
27. Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood. 2002;100(10):3639-3645.
28. Nishimura M, Yamada T, Andoh T, et al. Granulocyte colony-stimulating factor (G-CSF) dependent hematopoiesis with monosomy 7 in a patient with severe aplastic anemia after ATG/ CsA/G-CSF combined therapy. Int J Hematol. 1998;68(2):203-211.
29. Jerez A, Sugimoto Y, Makishima H, et al. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood. 2012;119(25):6109-6117.
30. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49(17):4682-4689.
31. Kadia TM, Kantarjian H, Kornblau S, et al. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer. 2012; 118(22):5550-5559.
32. Muramatsu H, Makishima H, Maciejewski JP. Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. Semin Oncol. 2012;39(1): 67-73.
33. Jankowska AM, Makishima H, Tiu RV, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011;118(14): 3932-3941.
34. Ayyadevara S, Thaden JJ, Shmookler Reis RJ. Discrimination of primer 3′-nucleotide mismatch by taq DNA polymerase during polymerase chain reaction. Anal Biochem. 2000;284(1):11-18.
35. Latorra D, Campbell K, Wolter A, Hurley JM. Enhanced allele-specific PCR discrimination in SNP genotyping using 3′ locked nucleic acid (LNA) primers. Hum Mutat. 2003;22(1): 79-85.
36. Rajala HL, Eldfors S, Kuusanmaki H, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013; 121(22):4541-4550.
37. Chen K, Wallis JW, McLellan MD, et al. BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods. 2009;6(9):677-681.